SG11201703669YA - Anti-cldn chimeric antigen receptors and methods of use - Google Patents
Anti-cldn chimeric antigen receptors and methods of useInfo
- Publication number
- SG11201703669YA SG11201703669YA SG11201703669YA SG11201703669YA SG11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA SG 11201703669Y A SG11201703669Y A SG 11201703669YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- chimeric antigen
- antigen receptors
- cldn
- cldn chimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2014/064165 WO2015069794A2 (en) | 2013-11-06 | 2014-11-05 | Novel anti-claudin antibodies and methods of use |
| US201562157928P | 2015-05-06 | 2015-05-06 | |
| US201562247108P | 2015-10-27 | 2015-10-27 | |
| PCT/US2015/059106 WO2016073649A1 (en) | 2014-11-05 | 2015-11-04 | Anti-cldn chimeric antigen receptors and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703669YA true SG11201703669YA (en) | 2017-06-29 |
Family
ID=55909771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703669YA SG11201703669YA (en) | 2014-11-05 | 2015-11-04 | Anti-cldn chimeric antigen receptors and methods of use |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20170334991A1 (en) |
| EP (1) | EP3215523A4 (en) |
| JP (1) | JP2017535283A (en) |
| KR (1) | KR20170085531A (en) |
| CN (1) | CN107207580A (en) |
| AU (1) | AU2015343079A1 (en) |
| BR (1) | BR112017009517A2 (en) |
| CA (1) | CA2966618A1 (en) |
| CL (1) | CL2017001118A1 (en) |
| CO (1) | CO2017005538A2 (en) |
| CR (1) | CR20170235A (en) |
| DO (1) | DOP2017000110A (en) |
| EA (1) | EA201790967A1 (en) |
| EC (1) | ECSP17031725A (en) |
| IL (1) | IL252090A0 (en) |
| MA (1) | MA40921A (en) |
| MX (1) | MX2017005797A (en) |
| PE (1) | PE20171060A1 (en) |
| PH (1) | PH12017500825A1 (en) |
| SG (1) | SG11201703669YA (en) |
| TW (1) | TW201625677A (en) |
| WO (1) | WO2016073649A1 (en) |
| ZA (1) | ZA201703471B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014346792A1 (en) * | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| US20190263927A1 (en) * | 2016-10-14 | 2019-08-29 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and eribulin for treating urothelial cancer |
| CA3177158A1 (en) | 2017-09-29 | 2019-04-04 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| WO2020114518A1 (en) * | 2018-12-07 | 2020-06-11 | 科济生物医药（上海）有限公司 | Tumor combined immunotherapy |
| WO2020143631A1 (en) * | 2019-01-07 | 2020-07-16 | 科济生物医药（上海）有限公司 | Cellular immunotherapy combination |
| US20210347847A1 (en) * | 2020-05-11 | 2021-11-11 | The Broad Institute, Inc. | Therapeutic targeting of malignant cells using tumor markers |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| JP2024512337A (en) * | 2021-03-05 | 2024-03-19 | シャンハイ、ケンパーソー、バイオテクノロジー、カンパニー、リミテッド | Anti-CLDN6 antibody and its use |
| CN114478802B (en) * | 2022-01-28 | 2023-05-26 | 郑州大学 | Chimeric antigen receptor and application thereof |
| CN117169518B (en) * | 2023-11-03 | 2024-01-19 | 赛德特(北京)生物工程有限公司 | Method and kit for detecting CD3 antibody residues in T lymphocyte preparation |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101074261A (en) * | 2006-04-30 | 2007-11-21 | 北京同为时代生物技术有限公司 | TRAIL receptor I and/or TRAIL receptor 2 specific antibody and its use |
| JP5374360B2 (en) * | 2007-02-27 | 2013-12-25 | 中外製薬株式会社 | Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient |
| CN101918450A (en) * | 2008-01-11 | 2010-12-15 | 国立大学法人东京大学 | Anti-CLDN6 antibody |
| NO2499161T3 (en) * | 2009-11-11 | 2018-02-03 | ||
| EP2404936A1 (en) * | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| EP3623380A1 (en) * | 2013-03-15 | 2020-03-18 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| AU2014346792A1 (en) * | 2013-11-06 | 2016-06-02 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
| HUE050355T2 (en) * | 2014-04-01 | 2020-12-28 | Biontech Cell & Gene Therapies Gmbh | Claudin-6-specific immunoreceptors and t cell epitopes |
| WO2016180467A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination |
| CA3006738A1 (en) * | 2015-12-04 | 2017-06-08 | Abbvie Stemcentrx Llc | Novel anti-claudin antibodies and methods of use |
-
2015
- 2015-11-03 MA MA040921A patent/MA40921A/en unknown
- 2015-11-04 BR BR112017009517A patent/BR112017009517A2/en not_active Application Discontinuation
- 2015-11-04 JP JP2017543306A patent/JP2017535283A/en active Pending
- 2015-11-04 CA CA2966618A patent/CA2966618A1/en not_active Abandoned
- 2015-11-04 EP EP15857690.0A patent/EP3215523A4/en not_active Withdrawn
- 2015-11-04 KR KR1020177015413A patent/KR20170085531A/en unknown
- 2015-11-04 WO PCT/US2015/059106 patent/WO2016073649A1/en active Application Filing
- 2015-11-04 AU AU2015343079A patent/AU2015343079A1/en not_active Abandoned
- 2015-11-04 PE PE2017000813A patent/PE20171060A1/en not_active Application Discontinuation
- 2015-11-04 CN CN201580072018.5A patent/CN107207580A/en active Pending
- 2015-11-04 EA EA201790967A patent/EA201790967A1/en unknown
- 2015-11-04 US US15/524,675 patent/US20170334991A1/en not_active Abandoned
- 2015-11-04 CR CR20170235A patent/CR20170235A/en unknown
- 2015-11-04 SG SG11201703669YA patent/SG11201703669YA/en unknown
- 2015-11-04 MX MX2017005797A patent/MX2017005797A/en unknown
- 2015-11-05 TW TW104136552A patent/TW201625677A/en unknown
-
2017
- 2017-05-02 DO DO2017000110A patent/DOP2017000110A/en unknown
- 2017-05-03 IL IL252090A patent/IL252090A0/en unknown
- 2017-05-04 PH PH12017500825A patent/PH12017500825A1/en unknown
- 2017-05-05 CL CL2017001118A patent/CL2017001118A1/en unknown
- 2017-05-19 ZA ZA2017/03471A patent/ZA201703471B/en unknown
- 2017-05-25 EC ECIEPI201731725A patent/ECSP17031725A/en unknown
- 2017-06-02 CO CONC2017/0005538A patent/CO2017005538A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201625677A (en) | 2016-07-16 |
| ZA201703471B (en) | 2019-06-26 |
| MX2017005797A (en) | 2017-10-23 |
| ECSP17031725A (en) | 2017-06-30 |
| EP3215523A1 (en) | 2017-09-13 |
| CA2966618A1 (en) | 2016-05-12 |
| WO2016073649A1 (en) | 2016-05-12 |
| IL252090A0 (en) | 2017-07-31 |
| MA40921A (en) | 2017-09-12 |
| JP2017535283A (en) | 2017-11-30 |
| DOP2017000110A (en) | 2017-05-31 |
| CO2017005538A2 (en) | 2017-10-10 |
| PH12017500825A1 (en) | 2017-10-18 |
| CR20170235A (en) | 2017-07-21 |
| AU2015343079A1 (en) | 2017-05-25 |
| EP3215523A4 (en) | 2018-06-20 |
| CN107207580A (en) | 2017-09-26 |
| BR112017009517A2 (en) | 2017-12-19 |
| US20170334991A1 (en) | 2017-11-23 |
| KR20170085531A (en) | 2017-07-24 |
| PE20171060A1 (en) | 2017-07-21 |
| EA201790967A1 (en) | 2017-10-31 |
| CL2017001118A1 (en) | 2018-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281819A (en) | Chimeric antigen receptors and methods of making | |
| IL252295A0 (en) | Chimeric antigen receptors and methods of use thereof | |
| HK1249405A1 (en) | Anti-dll3 chimeric antigen receptors and methods of use | |
| IL255336A0 (en) | Chimeric antigen receptors and methods of their use | |
| IL262041A (en) | Chimeric receptors and methods of use thereof | |
| HK1243102A1 (en) | Anti-cd79b antibodies and methods of use | |
| HRP20181359T1 (en) | Anti-jagged1 antibodies and methods of use | |
| IL251868B (en) | Anti-tim3 antibodies and methods of use | |
| IL252604A0 (en) | Chimeric antigen receptors and methods of use | |
| IL251165A0 (en) | Anti-il-1beta antibodies and methods of use | |
| ZA201703471B (en) | Anti-cldn chimeric antigen receptors and methods of use | |
| IL251286A0 (en) | Anti-pdgf-b antibodies and methods of use | |
| AU2016222891A1 (en) | Anti-DLL3 chimeric antigen receptors and methods of use |